Developer docs
API playgroundTry for free, no card

Search company profiles

Harmony Biosciences

Full company profile

uuid000282c

Namestring
Harmony Biosciences
Legal namestring
Harmony Biosciences Holdings, Inc.
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Harmony Biosciences Holdings, Inc. is a publicly traded (NASDAQ: HRMY) commercial-stage pharmaceutical company founded in 2017 by Paragon Biosciences, headquartered in Plymouth Meeting, Pennsylvania. The company develops and commercializes therapies for rare neurological disorders, with a primary focus on sleep/wake conditions and rare epilepsies. Its commercial product, WAKIX (pitolisant), is a histamine-3 receptor (H3R) antagonist/inverse agonist licensed from Bioprojet and is the first and only FDA-approved non-scheduled treatment for excessive daytime sleepiness and cataplexy in narcolepsy, now approved for both adults and pediatric patients aged 6 and older following a February 2026 label expansion.

The company's pipeline targets additional indications and mechanism diversification. Sleep/wake assets include Pitolisant GR (gastro-resistant, NDA filed Q2 2026) and Pitolisant HD (higher-dose) life-cycle extensions of the lead franchise, the orexin-2 receptor agonist BP-205 (Phase 1, initiated November 2025), the MCHR1 antagonist HBS-102, and regenerative cellular therapies CBS-105 and CBS-104 developed with CiRC Biosciences. Rare epilepsy assets include EPX-100 (Phase 3 ARGUS trial in Dravet syndrome and LIGHTHOUSE in Lennox-Gastaut syndrome) and EPX-200, both acquired through the April 2024 Epygenix Therapeutics acquisition; clemizole holds FDA orphan drug and rare pediatric disease designations.

Commercially, Harmony generates revenue through WAKIX prescription sales distributed via retail and specialty pharmacies in the United States, supported by a field sales force targeting sleep specialists and neurologists, patient support programs, and patient advocacy partnerships. The company grew full-year 2025 net product revenue to $868.5 million (22% YoY), guided to $1.00-$1.04 billion for 2026, and reported a 76.55% trailing-twelve-month gross margin with GAAP net income of $158.7 million and $882.5 million in cash reserves at year-end 2025. The acquisition of Epygenix (2024) and the previously acquired Zynerba Pharmaceuticals (2023) extend the company beyond a single-asset franchise, while a December 2025 partnership with Beacon Biosignals introduces AI-driven EEG endpoints into the HBS-301 Phase 3 program.

Short descriptiontext

Harmony Biosciences is a publicly traded commercial-stage pharmaceutical company that develops and commercializes therapies for rare neurological disorders, led by WAKIX (pitolisant), the first FDA-approved non-scheduled treatment for narcolepsy, serving approximately 8,500 patients with 2025 revenue of $868.5 million.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersPlymouth Meeting, United States
HQ citystring
Plymouth Meeting
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare neurological therapeutics, narcolepsy treatment, CNS pharmaceuticals, sleep wake disorders, rare epilepsy drugs
Industry4 codes
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Rare Neurological Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1WAKIX (Pitolisant) Product Sales
TypeOne Time License
Description

Primary revenue driver from sales of FDA-approved WAKIX tablets for narcolepsy. The product achieved $868.5 million in full-year 2025 net product revenue, representing 22% year-over-year growth. The company guides to over $1 billion in 2026 revenue, positioning WAKIX as a blockbuster drug. Revenue is generated through prescription sales distributed through pharmacies to patients with narcolepsy and related sleep disorders.

stocktitan.net
2Milestone Payments from Acquisitions
TypeLicensing Royalties
Description

The company has structured acquisitions with potential milestone payments. The Epygenix Therapeutics acquisition involves up to $550 million in milestone payments based on development, regulatory, and sales targets for EPX-100 and EPX-200. The Zynerba Pharmaceuticals acquisition includes up to $140 million in potential additional payments based on milestones.

ir.harmonybiosciences.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1WAKIX
Description

FDA-approved treatment for narcolepsy (excessive daytime sleepiness and cataplexy)

harmonybiosciences.com
+2 more records
Core offering1 text field

Harmony Biosciences develops and commercializes FDA-approved pharmaceutical therapies for rare neurological diseases. Its commercial product, WAKIX (pitolisant), is the first and only FDA-approved non-scheduled treatment for excessive daytime sleepiness and cataplexy in narcolepsy patients (adults and pediatric patients 6+). The company is expanding its pipeline with next-generation pitolisant formulations, orexin-2 receptor agonists, and rare epilepsy therapies acquired through M&A.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Approximately 50% median reduction in countable motor seizure frequency in Dravet syndrome patients treated with EPX-100
+2 more records
Product overview1 text field

Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for rare neurological diseases. The company's commercial product is WAKIX (pitolisant), an FDA-approved treatment for excessive daytime sleepiness and cataplexy in narcolepsy (adults and children 6+). The pipeline spans sleep/wake disorders and rare epilepsy syndromes. Next-generation pitolisant formulations include Pitolisant GR (gastro-resistant, NDA submitted Q2 2026) and Pitolisant HD (higher dose, Phase 3 planned 2027). The rare epilepsy pipeline includes EPX-100 and EPX-200 acquired from Epygenix Therapeutics (2024), plus early-stage programs (HBS-102, CBS-105, CBS-104) developed in research collaboration with CiRC Biosciences. The company also acquired Zynerba Pharmaceuticals (2023) for neuropsychiatric disorder treatments.

Product and service3 records
1WAKIX (pitolisant)
CategoryCommercial Pharmaceutical Product
Description

FDA-approved histamine-3 receptor antagonist/inverse agonist for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy; expanded in 2026 to include pediatric patients 6 years and older. The first and only FDA-approved non-scheduled therapy for narcolepsy, distributed by prescription through retail and specialty pharmacies in the United States.

2EPX-100 (clemizole hydrochloride)
CategoryPipeline - Rare Epilepsy
Description

Investigational compound modulating serotonin signaling by targeting central 5-hydroxytryptamine (5-HT) receptor subtypes. Granted FDA orphan drug designation for Dravet syndrome and Lennox-Gastaut syndrome, and FDA rare pediatric disease designation for both indications. Phase 3 ARGUS trial ongoing in Dravet syndrome; Phase 3 LIGHTHOUSE trial planned in LGS; approximately 50% median reduction in motor seizure frequency observed in Dravet open-label extension.

3EPX-200 (lorcaserin)
CategoryPipeline - Rare Epilepsy
Description

Potent, oral, centrally active and selective 5HT2C agonist in IND-enabling studies. Liquid formulation of lorcaserin targeting Developmental and Epileptic Encephalopathies.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Exclusive license agreement to develop, manufacture, and commercialize pitolisant in the United States. Pitolisant was designed and developed by Bioprojet and approved in Europe by the European Medicines Agency in 2016.

2Epygenix Therapeutics, Inc.
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Acquired in February 2024, expanding pipeline with clinical-stage drugs EPX-100 and EPX-200 for rare epilepsy treatments including Dravet syndrome and Lennox-Gastaut syndrome. Deal involves up to $550 million in milestone payments based on development, regulatory, and sales targets. Potential peak sales over $1 billion each.

ir.harmonybiosciences.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Acquired in August 2023 for $60 million in cash with potential additional payments up to $140 million based on milestones. Expanded portfolio with Zynerba's neuropsychiatric disorder treatments including Phase 3 clinical trial for Fragile X syndrome. The ZYN002 program was subsequently discontinued following Phase 3 trial failure.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration for CBS-105 and CBS-104, investigational novel regenerative cellular therapies aimed at replacing lost neurons and restoring function in patients with treatment-resistant narcolepsy and refractory epilepsy.

Recent move13 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Jazz commercializes Xywav and Lumryz for narcolepsy, directly competing with WAKIX in the same prescriber base of sleep specialists and neurologists. Both companies pursue CNS/rare neurology franchises with similar field-sales-driven commercialization models.

TypeBroad incumbent
Description

Takeda is a global rare disease and CNS player where multiple Harmony executives previously held senior roles. Its rare disease commercial infrastructure and product launches in neurology/rare epilepsy make it a structural incumbent comparable.

TypeEmerging player
Description

Zevra focuses on rare CNS diseases with arimoclomol for Niemann-Pick type C and SDX (serdexmethylphenidate) for narcolepsy. It overlaps Harmony in the rare neurology/sleep category at a smaller scale with similar orphan-drug development approach.

TypeDirect peer
Description

Avadel's Lumryz (sodium oxybate) competes with WAKIX in narcolepsy treatment, targeting the same EDS/cataplexy patient population. Both companies are mid-cap rare neurology specialists listed on NASDAQ with single-asset commercial franchises.

TypeEmerging player
Description

BioXcel commercializes IGALMI for CNS agitation and develops BXCL501/BXCL502 in neurology/immunology. It is a comparable early-commercial rare/specialty CNS biotech targeting similar prescriber bases with a focused pipeline model.

TypeBroad incumbent
Description

Intra-Cellular Therapies (acquired by J&J) built Caplyta for CNS indications through similar specialty sales-force-led commercialization. Its trajectory from single-asset to platform CNS franchise mirrors Harmony's strategic trajectory.

TypeBroad incumbent
Description

UCB is a global biopharma with significant rare neurology and epilepsy franchises (Fintepla, Briviact, Vimpat). Its rare epilepsy focus particularly overlaps Harmony's EPX-100/EPX-200 Dravet and Lennox-Gastaut programs.

TypeBroad incumbent
Description

Lundbeck is a global CNS specialty pharma where Harmony's new COO Peter Anastasiou previously led North America. Its broad neurology portfolio (Vyepti, Onfi) serves as a strategic incumbent comparator for global CNS commercialization.

TypeBroad incumbent
Description

Supernus is a CNS-focused specialty pharma with a broader neurology portfolio (Qelbree, Apokyn) targeting similar specialty prescriber channels. It serves as a comparable commercial-stage CNS specialty pharma business model with diversified revenue.

TypeDirect peer
Description

Axsome is developing AXS-12 for narcolepsy alongside its CNS portfolio, positioning it as a direct therapeutic competitor to WAKIX. Both companies target rare CNS indications with novel mechanisms and pursue similar specialty-pharma growth profiles.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Harmony Biosciences

Rare Neurological Pharmaceuticalsharmonybiosciences.com

Harmony Biosciences is a publicly traded commercial-stage pharmaceutical company that develops and commercializes therapies for rare neurological disorders, led by WAKIX (pitolisant), the first FDA-approved non-scheduled treatment for narcolepsy, serving approximately 8,500 patients with 2025 revenue of $868.5 million.

What Harmony Biosciences does

Harmony Biosciences Holdings, Inc. is a publicly traded (NASDAQ: HRMY) commercial-stage pharmaceutical company founded in 2017 by Paragon Biosciences, headquartered in Plymouth Meeting, Pennsylvania. The company develops and commercializes therapies for rare neurological disorders, with a primary focus on sleep/wake conditions and rare epilepsies. Its commercial product, WAKIX (pitolisant), is a histamine-3 receptor (H3R) antagonist/inverse agonist licensed from Bioprojet and is the first and only FDA-approved non-scheduled treatment for excessive daytime sleepiness and cataplexy in narcolepsy, now approved for both adults and pediatric patients aged 6 and older following a February 2026 label expansion.

The company's pipeline targets additional indications and mechanism diversification. Sleep/wake assets include Pitolisant GR (gastro-resistant, NDA filed Q2 2026) and Pitolisant HD (higher-dose) life-cycle extensions of the lead franchise, the orexin-2 receptor agonist BP-205 (Phase 1, initiated November 2025), the MCHR1 antagonist HBS-102, and regenerative cellular therapies CBS-105 and CBS-104 developed with CiRC Biosciences. Rare epilepsy assets include EPX-100 (Phase 3 ARGUS trial in Dravet syndrome and LIGHTHOUSE in Lennox-Gastaut syndrome) and EPX-200, both acquired through the April 2024 Epygenix Therapeutics acquisition; clemizole holds FDA orphan drug and rare pediatric disease designations.

Commercially, Harmony generates revenue through WAKIX prescription sales distributed via retail and specialty pharmacies in the United States, supported by a field sales force targeting sleep specialists and neurologists, patient support programs, and patient advocacy partnerships. The company grew full-year 2025 net product revenue to $868.5 million (22% YoY), guided to $1.00-$1.04 billion for 2026, and reported a 76.55% trailing-twelve-month gross margin with GAAP net income of $158.7 million and $882.5 million in cash reserves at year-end 2025. The acquisition of Epygenix (2024) and the previously acquired Zynerba Pharmaceuticals (2023) extend the company beyond a single-asset franchise, while a December 2025 partnership with Beacon Biosignals introduces AI-driven EEG endpoints into the HBS-301 Phase 3 program.

Harmony Biosciences firmographics

Firmographics
Name
Harmony Biosciences
Legal name
Harmony Biosciences Holdings, Inc.
Website
https://harmonybiosciences.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
251–500 employees
Short description
Harmony Biosciences is a publicly traded commercial-stage pharmaceutical company that develops and commercializes therapies for rare neurological disorders, led by WAKIX (pitolisant), the first FDA-approved non-scheduled treatment for narcolepsy, serving approximately 8,500 patients with 2025 revenue of $868.5 million.
Ownership category
akta.pro rank

Harmony Biosciences industry classification

Industry
Product category
Rare Neurological Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare neurological therapeutics
  • Narcolepsy treatment
  • CNS pharmaceuticals
  • Sleep wake disorders
  • Rare epilepsy drugs

Where Harmony Biosciences is headquartered

Location

Headquarters

HQ city
Plymouth Meeting
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Harmony Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain

Revenue model

  1. WAKIX (Pitolisant) Product Sales: Primary revenue driver from sales of FDA-approved WAKIX tablets for narcolepsy. The product achieved $868.5 million in full-year 2025 net product revenue, representing 22% year-over-year growth. The company guides to over $1 billion in 2026 revenue, positioning WAKIX as a blockbuster drug. Revenue is generated through prescription sales distributed through pharmacies to patients with narcolepsy and related sleep disorders.
  2. Milestone Payments from Acquisitions: The company has structured acquisitions with potential milestone payments. The Epygenix Therapeutics acquisition involves up to $550 million in milestone payments based on development, regulatory, and sales targets for EPX-100 and EPX-200. The Zynerba Pharmaceuticals acquisition includes up to $140 million in potential additional payments based on milestones.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Harmony Biosciences product offering

Product offering

Core offering

Harmony Biosciences develops and commercializes FDA-approved pharmaceutical therapies for rare neurological diseases. Its commercial product, WAKIX (pitolisant), is the first and only FDA-approved non-scheduled treatment for excessive daytime sleepiness and cataplexy in narcolepsy patients (adults and pediatric patients 6+). The company is expanding its pipeline with next-generation pitolisant formulations, orexin-2 receptor agonists, and rare epilepsy therapies acquired through M&A.

Product overview

Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for rare neurological diseases. The company's commercial product is WAKIX (pitolisant), an FDA-approved treatment for excessive daytime sleepiness and cataplexy in narcolepsy (adults and children 6+). The pipeline spans sleep/wake disorders and rare epilepsy syndromes. Next-generation pitolisant formulations include Pitolisant GR (gastro-resistant, NDA submitted Q2 2026) and Pitolisant HD (higher dose, Phase 3 planned 2027). The rare epilepsy pipeline includes EPX-100 and EPX-200 acquired from Epygenix Therapeutics (2024), plus early-stage programs (HBS-102, CBS-105, CBS-104) developed in research collaboration with CiRC Biosciences. The company also acquired Zynerba Pharmaceuticals (2023) for neuropsychiatric disorder treatments.

Differentiator

Problem solved

Functional benefit

Brands

  • WAKIX: FDA-approved treatment for narcolepsy (excessive daytime sleepiness and cataplexy)
  • Know Narcolepsy
  • Newrology

Products and services

  • WAKIX (pitolisant) FDA-approved histamine-3 receptor antagonist/inverse agonist for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy; expanded in 2026 to include pediatric patients 6 years and older. The first and only FDA-approved non-scheduled therapy for narcolepsy, distributed by prescription through retail and specialty pharmacies in the United States.
  • EPX-100 (clemizole hydrochloride) Investigational compound modulating serotonin signaling by targeting central 5-hydroxytryptamine (5-HT) receptor subtypes. Granted FDA orphan drug designation for Dravet syndrome and Lennox-Gastaut syndrome, and FDA rare pediatric disease designation for both indications. Phase 3 ARGUS trial ongoing in Dravet syndrome; Phase 3 LIGHTHOUSE trial planned in LGS; approximately 50% median reduction in motor seizure frequency observed in Dravet open-label extension.
  • EPX-200 (lorcaserin) Potent, oral, centrally active and selective 5HT2C agonist in IND-enabling studies. Liquid formulation of lorcaserin targeting Developmental and Epileptic Encephalopathies.

Quantifiable outcome

  • Approximately 50% median reduction in countable motor seizure frequency in Dravet syndrome patients treated with EPX-100
  • +2 more outcomes

Companies that use Harmony Biosciences

Customer profile

Named customers1 record

Segments6 records

Ideal customer profiles3 records

Harmony Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Harmony Biosciences partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Bioprojet Societe Civile de RecherchecoreStrategic or Co-development PartnerExclusive license agreement to develop, manufacture, and commercialize pitolisant in the United States. Pitolisant was designed and developed by Bioprojet and approved in Europe by the European Medicines Agency in 2016.
  • Epygenix Therapeutics, Inc.coreStrategic or Co-development PartnerAcquired in February 2024, expanding pipeline with clinical-stage drugs EPX-100 and EPX-200 for rare epilepsy treatments including Dravet syndrome and Lennox-Gastaut syndrome. Deal involves up to $550 million in milestone payments based on development, regulatory, and sales targets. Potential peak sales over $1 billion each.
  • Zynerba Pharmaceuticals, Inc.coreStrategic or Co-development PartnerAcquired in August 2023 for $60 million in cash with potential additional payments up to $140 million based on milestones. Expanded portfolio with Zynerba's neuropsychiatric disorder treatments including Phase 3 clinical trial for Fragile X syndrome. The ZYN002 program was subsequently discontinued following Phase 3 trial failure.
  • CiRC BiosciencesminorStrategic or Co-development PartnerResearch collaboration for CBS-105 and CBS-104, investigational novel regenerative cellular therapies aimed at replacing lost neurons and restoring function in patients with treatment-resistant narcolepsy and refractory epilepsy.

Scale indicators8 records

Recent moves13 records

Expansion highlights6 records

Harmony Biosciences competitors and assessment

Company assessment

Direct peers

  • Jazz Pharmaceuticals: Jazz commercializes Xywav and Lumryz for narcolepsy, directly competing with WAKIX in the same prescriber base of sleep specialists and neurologists. Both companies pursue CNS/rare neurology franchises with similar field-sales-driven commercialization models.
  • Avadel Pharmaceuticals: Avadel's Lumryz (sodium oxybate) competes with WAKIX in narcolepsy treatment, targeting the same EDS/cataplexy patient population. Both companies are mid-cap rare neurology specialists listed on NASDAQ with single-asset commercial franchises.
  • Axsome Therapeutics: Axsome is developing AXS-12 for narcolepsy alongside its CNS portfolio, positioning it as a direct therapeutic competitor to WAKIX. Both companies target rare CNS indications with novel mechanisms and pursue similar specialty-pharma growth profiles.

Broad incumbents

  • Takeda Pharmaceutical: Takeda is a global rare disease and CNS player where multiple Harmony executives previously held senior roles. Its rare disease commercial infrastructure and product launches in neurology/rare epilepsy make it a structural incumbent comparable.
  • Intra-Cellular Therapies: Intra-Cellular Therapies (acquired by J&J) built Caplyta for CNS indications through similar specialty sales-force-led commercialization. Its trajectory from single-asset to platform CNS franchise mirrors Harmony's strategic trajectory.
  • UCB: UCB is a global biopharma with significant rare neurology and epilepsy franchises (Fintepla, Briviact, Vimpat). Its rare epilepsy focus particularly overlaps Harmony's EPX-100/EPX-200 Dravet and Lennox-Gastaut programs.
  • Lundbeck: Lundbeck is a global CNS specialty pharma where Harmony's new COO Peter Anastasiou previously led North America. Its broad neurology portfolio (Vyepti, Onfi) serves as a strategic incumbent comparator for global CNS commercialization.
  • Supernus Pharmaceuticals: Supernus is a CNS-focused specialty pharma with a broader neurology portfolio (Qelbree, Apokyn) targeting similar specialty prescriber channels. It serves as a comparable commercial-stage CNS specialty pharma business model with diversified revenue.

Emerging players

  • Zevra Therapeutics: Zevra focuses on rare CNS diseases with arimoclomol for Niemann-Pick type C and SDX (serdexmethylphenidate) for narcolepsy. It overlaps Harmony in the rare neurology/sleep category at a smaller scale with similar orphan-drug development approach.
  • BioXcel Therapeutics: BioXcel commercializes IGALMI for CNS agitation and develops BXCL501/BXCL502 in neurology/immunology. It is a comparable early-commercial rare/specialty CNS biotech targeting similar prescriber bases with a focused pipeline model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Harmony Biosciences social profiles

Digital presence

Harmony Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Harmony Biosciences leadership team

Management profile

Number of profiles

Profiles12 records

Harmony Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Harmony Biosciences funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Harmony Biosciences M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Harmony Biosciences

What does Harmony Biosciences do?

Harmony Biosciences develops and commercializes FDA-approved pharmaceutical therapies for rare neurological diseases. Its commercial product, WAKIX (pitolisant), is the first and only FDA-approved non-scheduled treatment for excessive daytime sleepiness and cataplexy in narcolepsy patients (adults and pediatric patients 6+). The company is expanding its pipeline with next-generation pitolisant formulations, orexin-2 receptor agonists, and rare epilepsy therapies acquired through M&A.

Is Harmony Biosciences a public or private company?

Harmony Biosciences is a public company. It is classified as public and is currently operating.

When was Harmony Biosciences founded?

Harmony Biosciences was founded in 2017. It employs 251 to 500 people.

Where is Harmony Biosciences based?

Harmony Biosciences is headquartered in Plymouth Meeting, United States, in the North America region.

How does Harmony Biosciences make money?

Two revenue lines are on record. WAKIX (Pitolisant) Product Sales are the primary driver. The others are milestone Payments from Acquisitions.

Who are Harmony Biosciences's main competitors?

Direct peers on record are Jazz Pharmaceuticals, Avadel Pharmaceuticals and Axsome Therapeutics. Broad incumbents are Takeda Pharmaceutical, Intra-Cellular Therapies, UCB, Lundbeck and Supernus Pharmaceuticals. Emerging players are Zevra Therapeutics and BioXcel Therapeutics.

Does Harmony Biosciences have an API?

No public API is recorded for Harmony Biosciences.

What industry is Harmony Biosciences in?

Harmony Biosciences's product category is Rare Neurological Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StHarmony Biosciences Holdings (HRMY) On Q3 Results And Reaffirmed Guidance Looks UndervaluedHarmony Biosciences Holdings reported Q3 results with softer quarterly earnings but higher year-to-date profit, reaffirming full-year revenue guidance of $1.0b to $1.04b. The stock is down about 11% over the past month, while the company's cash position of $962.5 million against $155 million debt supports R&D. Analysts see a fair value of $47.64, implying undervaluation.Simply Wall StWill Mixed Earnings Results Change Harmony Biosciences Holdings (HRMY) NarrativeHarmony Biosciences Holdings reported Q3 2026 net income of $48.2 million, with diluted EPS of $0.81, and nine-month net income of $156.12 million, diluted EPS $2.63. The quarter's EPS dip contrasts with higher nine-month earnings, while analysts project $1.4B revenue and $363.2M earnings by 2029, implying a 41% upside.American Banking and Market NewsHarmony Biosciences (NASDAQ:HRMY) Cut to “Hold” at Wall Street ZenWall Street Zen downgraded Harmony Biosciences from Buy to Hold. The company reported Q3 EPS of $0.81, missing the $1.09 consensus, while revenue rose 12.3% to $268.92 million. Analysts expect FY EPS of $3.69.MarketScreenerHarmony Biosciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Harmony Biosciences reported Q3 net income of $48.2 million, down from $50.87 million a year ago, with diluted EPS of $0.81 versus $0.87. For the nine months, net income was $156.12 million, up from $136.2 million, and diluted EPS was $2.63 versus $2.32.ChartmillHarmony Biosciences Holdings (NASDAQ:HRMY) Q3 2026 Earnings Miss Overshadows WAKIX GrowthHarmony Biosciences reported Q3 2026 WAKIX net revenue of $268.9 million, down 3.4% from consensus, and EPS of $0.81, 30% below the $1.16 consensus. The company reiterated full-year WAKIX revenue guidance of $1.0–$1.04 billion, while the market fell 3.4% premarket. Pipeline updates and leadership transition were disclosed but did not offset the earnings miss.Investing.comHarmony Biosciences Holdings earnings missed by $0.30, revenue fell short of estimatesHarmony Biosciences Holdings reported Q3 EPS of $0.81, $0.30 below the $1.11 estimate, and revenue of $268.91M, short of the $274.55M consensus. The company guided FY2026 revenue to $1,000M-$1.04B, below the $1.02B analyst consensus. Stock closed at $37.02, down 3.62% over three months.Quiver QuantitativeHARMONY BIOSCIENCES ($HRMY) Releases Q3 2026 Earnings | HRMY Stock NewsHARMONY BIOSCIENCES reported Q3 2026 earnings of $0.81 per share, missing the $1.16 estimate, and revenue of $268.92 million, below the $278.54 million estimate. Insiders made four sales in the past six months, and hedge fund activity shows mixed moves, with some large reductions.American Banking and Market NewsHarmony Biosciences Holdings, Inc. $HRMY Stock: Bridge City Capital LLC Boosts PositionBridge City Capital LLC raised its Harmony Biosciences stake by 26.5% in Q3, buying 55,539 shares. The company reported Q3 EPS of $1.28, beating estimates, with revenue up 30.3% year-over-year. Analysts have a consensus price target of $48.00.MarketBeatHarmony Biosciences (NASDAQ:HRMY) Rating Lowered to "Buy" at Wall Street ZenWall Street Zen lowered Harmony Biosciences from a strong-buy to a buy rating. The company reported Q2 EPS of $1.28, beating estimates, with revenue of $261.28 million, up 30.3% year-over-year. Analysts have a consensus Moderate Buy rating with a $48 target.American Banking and Market NewsHarmony Biosciences (NASDAQ:HRMY) Downgraded by Wall Street Zen to BuyWall Street Zen downgraded Harmony Biosciences from strong-buy to buy. The stock opened at $38.76, with a consensus target of $48.00 and a Moderate Buy rating. Analysts predict 3.76 EPS for the current fiscal year.